A public joint-stock company established in 1986, Spimaco Pharmaceutical and its subsidiaries primarily engage in pharmaceutical and medical production activities. This includes the manufacturing, production, development, marketing, sale, and distribution of pharmaceutical raw materials, medical and pharmaceutical preparations, production supplies, medical devices, and consumable medical supplies, as well as investment activities in various companies inside and outside the Kingdom of Saudi Arabia. In 2022, Spimaco completed a series of enhancements to its capabilities and operations to restructure its core business and capitalize on long-term sustainable market opportunities. The company also entered into agreements and strengthened partnerships and alliances with global companies to produce key drugs and dietary supplements and to register new products. The company signed a memorandum of understanding with SABIC to support the localization of the active pharmaceutical ingredients sector, aiming to develop and produce several active pharmaceutical ingredients and enhance the operational efficiency of the factory. Additionally, the European Patent Office granted the company its first patent for a new pharmaceutical product. The company opened its new factory for producing cancer drugs and highly toxic medications in Al-Qassim in partnership with AstraZeneca. It is noteworthy that the company continues to maintain its leading position among private sector companies in the Saudi market and export markets. The company’s capital is 1.2 billion Saudi riyals (approximately 97.2 million Kuwaiti dinars), with ACDIMA holding a 20.488% stake in the company's capital. The total sales revenue for the company in 2022 was approximately 116 million Kuwaiti dinars compared to about 118 million Kuwaiti dinars in 2021, and the company recorded a net loss of 14 million Kuwaiti dinars in 2022 compared to a profit of about 1.5 million Kuwaiti dinars in 2021.